Pure Financial Advisors buys $359,354 stake in Baxter International Inc (BAX)

Baxter International Inc (BAX) : Pure Financial Advisors scooped up 22 additional shares in Baxter International Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 7,417 shares of Baxter International Inc which is valued at $359,354.Baxter International Inc makes up approximately 0.12% of Pure Financial Advisors’s portfolio.

Other Hedge Funds, Including , Catawba Capital Management Va boosted its stake in BAX in the latest quarter, The investment management firm added 1,200 additional shares and now holds a total of 72,256 shares of Baxter International Inc which is valued at $3,500,803. Baxter International Inc makes up approx 0.84% of Catawba Capital Management Va’s portfolio. Independent Portfolio Consultants sold out all of its stake in BAX during the most recent quarter. The investment firm sold 427 shares of BAX which is valued $20,462.Chevy Chase Trust Holdings reduced its stake in BAX by selling 62,678 shares or 12.73% in the most recent quarter. The Hedge Fund company now holds 429,601 shares of BAX which is valued at $20,586,480. Baxter International Inc makes up approx 0.11% of Chevy Chase Trust Holdings’s portfolio.Lvm Capital Management Ltdmi boosted its stake in BAX in the latest quarter, The investment management firm added 110,246 additional shares and now holds a total of 116,480 shares of Baxter International Inc which is valued at $5,581,722. Baxter International Inc makes up approx 1.76% of Lvm Capital Management Ltdmi’s portfolio.

Baxter International Inc opened for trading at $48.37 and hit $48.55 on the upside on Friday, eventually ending the session at $48.45, with a gain of 0.48% or 0.23 points. The heightened volatility saw the trading volume jump to 35,83,251 shares. Company has a market cap of $26,351 M.

On the company’s financial health, Baxter International Inc reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.40. The company had revenue of $2585.00 million for the quarter, compared to analysts expectations of $2516.16 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.

Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Jul 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 50 from a previous price target of $47 .

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.